Nevro Corp. (NVRO)

Market Cap	218.94M
Revenue (ttm)	408.52M
Net Income (ttm)	-113.44M
Shares Out	37.88M
EPS (ttm)	-3.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,105,658
Open	5.80
Previous Close	5.79
Day's Range	5.78 - 5.80
52-Week Range	3.17 - 14.89
Beta	0.94
Analysts	Hold
Price Target	7.24 (+25.26%)
Earnings Date	Mar 4, 2025

About NVRO

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial st...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 1,215
• Stock Exchange: NYSE
• Ticker Symbol: NVRO
• Website: https://nevro.com

Financial Performance

In 2024, Nevro's revenue was $408.52 million, a decrease of -3.92% compared to the previous year's $425.17 million. Losses were -$113.44 million, 23.0% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for NVRO stock is "Hold." The 12-month stock price forecast is $7.24, which is an increase of 25.26% from the latest price.

Price Target

$7.24

(25.26% upside)

Analyst Consensus: Hold